Drug Trial Radar · NCT06327256
A Study in Healthy People to Test How Well Different Doses of BI 3000202 Are Tolerated and How They Affect the Way the Body Handles Midazolam
Last checked: Nov 20, 2026Latest source record: Nov 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Apr 9, 2024
Primary completion
Sep 27, 2024
Study completion Sep 27, 2024
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Mar 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) following multiple rising doses of BI 3000202 and to investigate the effect of BI 3000202 on the metabolism of midazolam.
Conditions
- Healthy
Interventions
BI 3000202Drug
BI 3000202
PlaceboDrug
Placebo-matching BI 3000202
MidazolamDrug
Midazolam
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of subjects with drug-related adverse eventsTime frame: Up to day 20
Locations
1 site in 1 country. Site status is shown where the registry gives one.
SGS Life Science Services - Clinical Research
Edegem, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.